SCHEMBL3229955

SCHEMBL3229955

CN1CCN(c2ccc(F)c(F)c2)c2ccc(-c3cnccn3)cc2C1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 1/20 0.44
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
SLC6A3 Q01959 2/20 0.41
DYRK1A Q13627 4/20 0.38
RPS6KA3 P51812 3/20 0.36
RPS6KA2 Q15349 1/20 0.36
RPS6KA1 Q15418 1/20 0.36
NR1I2 O75469 1/20 0.35
HSD11B1 P28845 1/20 0.35
DHFR P00374 1/20 0.35
PIM1 P11309 1/20 0.35
PIM3 Q86V86 1/20 0.35
PIM2 Q9P1W9 1/20 0.35
GSK3B P49841 2/20 0.35
ALDH1A1 P00352 1/20 0.35
HDAC3 O15379 1/20 0.34
HDAC1 Q13547 1/20 0.34
HDAC2 Q92769 1/20 0.34
KCNH2 Q12809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3222166 0.89 SCN9A (0.47) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3227292 0.87 SCN9A (0.43) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3225109 0.87 SLC6A2 (0.48) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3232604 0.87 SCN9A (0.45) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3238925 0.86 SCN9A (0.48) SCN9ADYRK1AGSK3BALDH1A1
SCHEMBL3226065 0.86 SCN9A (0.45) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3232265 0.85 SCN9A (0.42) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3234067 0.85 SCN9A (0.46) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3230207 0.84 SLC6A2 (0.46) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A
SCHEMBL3226298 0.84 SCN9A (0.45) SCN9ASLC6A2SLC6A4SLC6A3DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096546-B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin ALBANY MOLECULAR RESEARCH, INC. (US) 2015-08-04 US disclosed
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ALBANY MOLECULAR RESEARCH, INC. (US) 2010-06-03 US disclosed
EP-2146722-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR Technology, Inc. (US) 2010-01-27 EP disclosed
WO-2008141081-A1 ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN AMR TECHNOLOGY, INC. (US) 2008-11-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137287-A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN ADRA1B, ADRB1, ADRA1D SCN9A 795/4885SLC6A2 28/4885SLC6A4 40/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.